Anti-Calcitonin, Mouse-Mono, 1µg (CB02-CT08)
Product#: CB02-CT08_1μg
$2,192.79
Availability:
Ships in 48 hours
Anti-Calcitonin, Mouse-Mono
Clone No: CT08
Cat. No: CB02-CT08_1μg
*This product was customized.
| Description: | Mouse anti-calcitonin monoclonal antibody, Clone No. CT08, unconjugated. |
| Immunogen: | Synthetic peptide of human calcitonin, conjugated with protein. |
| Form: | Solution in Dulbecco’s Phosphate-Buffered Saline (modified) containing 0.03% ProClin. |
| Quanitity: | 1µg (*This product was customized.) |
| Concentration: | 0.9 - 1.1 mg/mL Determined by extinction coefficient, absorbance at 280nm of 1.38 equals 1.0 mg of IgG (E1%1cm =13.8). |
| Purification: | Affinity chromatography using protein G. |
| Application: | Calcitonin immunoassay |
| Subclass: | IgG1 |
| Specificity: | React to carboxylic acid amide terminus of human calcitonin. This antibody showed weak cross-reactivity to rat calcitonin, but not cross-react with salmon, chicken and porcine calcitonin. |
| Long Term Storage: | -20°C or below |
| Shipping Condition: | Dry Ice |
| Note: | For research use only. |
Calibration curve of calcitonin sandwich immunoassay
Antigen Characterization
- Type: Primary
- Application: ELISA, Western Blot, Immunohistochemistry, Radioimmunoassay
- Species: Mouse
- Recombinant:Yes
Human Diseases
- Paget's Disease: Calcitonin has been used in the treatment of Paget's disease, a condition that disrupts the normal process of bone remodeling, leading to enlarged and weakened bones.
- Hypercalcemia: Calcitonin is effective in managing hypercalcemia, which can occur in conditions like malignancy and hyperparathyroidism, where there is an excess of calcium in the blood.
- Thyroid Carcinoma: The calcitonin receptor is expressed in medullary thyroid carcinoma, and calcitonin levels can be a marker for this type of cancer.
- Bone Metastases: Calcitonin may help in managing bone pain associated with bone metastases from cancers, as it has a role in bone metabolism and calcium regulation.
- Osteoporosis: Calcitonin has been studied for its potential benefits in treating osteoporosis, particularly in postmenopausal women, as it can help to reduce bone loss.
- Migraine: Calcitonin gene-related peptide (CGRP), related to calcitonin, is implicated in migraine pathophysiology, and therapies targeting CGRP are used for migraine treatment.
Cellular Signaling Pathways
- cAMP Pathway: Calcitonin binding to its receptor activates adenylate cyclase via Gs proteins, leading to an increase in cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP activates protein kinase A (PKA), which then phosphorylates various target proteins, influencing cellular responses such as:
- Inhibition of osteoclast activity: This reduces bone resorption and lowers blood calcium levels.
- Regulation of renal tubular reabsorption: Calcitonin promotes calcium excretion in the kidneys.
- Phospholipase C Pathway
- In some tissues, calcitonin can activate phospholipase C (PLC) via Gq proteins. This results in the production of inositol trisphosphate (IP3) and diacylglycerol (DAG), leading to:
- Calcium release from the endoplasmic reticulum: Increased intracellular calcium can further influence various cellular processes.
- Activation of protein kinase C (PKC):
- PKC activation plays a role in various signaling cascades, including cell proliferation and differentiation.
- MAPK Pathway
- Calcitonin can also activate the mitogen-activated protein kinase (MAPK) pathway, which is involved in cell growth and differentiation. This pathway can be activated through various mechanisms, including the cAMP pathway and direct receptor signaling.
Aliases for Calcitonin Gene
- Thyrocalcitonin
- CALC1
- CALCA
- CT
References
- Kee, Zizheng, et al. “The Role of Calcitonin Gene Related Peptide (CGRP) in Neurogenic Vasodilation and Its Cardioprotective Effects.” Frontiers, Frontiers, 17 Aug. 2018, www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2018.01249/full.
- Hou, Y., Lin, B., Xu, T. et al. The neurotransmitter calcitonin gene-related peptide shapes an immunosuppressive microenvironment in medullary thyroid cancer. Nat Commun 15, 5555 (2024). https://doi.org/10.1038/s41467-024-49824-7
- Kiriakopoulos, Andreas et al. “Calcitonin: current concepts and differential diagnosis.” Therapeutic advances in endocrinology and metabolism vol. 13 20420188221099344. 21 May. 2022, doi:10.1177/20420188221099344
- “Calcitonin (Thyrocalcitonin).” Labcorp, www.labcorp.com/tests/004895/calcitonin-thyrocalcitonin.
- McLaughlin MB, Awosika AO, Jialal I. Calcitonin. [Updated 2023 Aug 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537269
